The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Quinolone antibiotics
Open accessAbstract
The quinolone antibiotics arose in the early 1960s, with the first examples possessing a narrow-spectrum activity with unfavorable pharmacokinetic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
On the Regulation of DNA Replication in Bacteria
Jacob, F., Brenner, S., & Cuzin, F. (1963) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1963.028.01.048 · Cited by 1,445
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Principles and Practice of Infectious Diseases
Larson, H. E. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.9.907-a · Cited by 1,276
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.007 · Cited by 1,008
Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat
Strahilevitz, J., Jacoby, G. A., Hooper, D. C., & Robicsek, A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-09 · Cited by 928
Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., & Tomizawa, J.-I. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4772 · Cited by 833
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962) · Journal of Medicinal and Pharmaceutical Chemistry · doi:10.1021/jm01240a021 · Cited by 766
An Introduction to Medicinal Chemistry
Patrick, G. L. (2023) · Oxford University Press eBooks · doi:10.1093/hesc/9780198866664.001.0001 · Cited by 756
Mechanisms of drug resistance: quinolone resistance
Hooper, D. C., & Jacoby, G. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12830 · Cited by 716
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Domagala, J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.4.685 · Cited by 681
Emerging Mechanisms of Fluoroquinolone Resistance
Hooper, D. C. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010239 · Cited by 633
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Quinolone-Mediated Bacterial Death
Drlica, K., Malik, M., Kerns, R. J., & Zhao, X. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01617-06 · Cited by 570
Mechanism of plasmid-mediated quinolone resistance
Tran, J. H., & Jacoby, G. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082092899 · Cited by 564
Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments
Hopkins, K. L., Davies, R. H., & Threlfall, E. J. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.02.006 · Cited by 557
Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance
Hooper, D. C., & Jacoby, G. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025320 · Cited by 553
The quinolones: decades of development and use
Emmerson, A. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg208 · Cited by 531
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
Andersson, M. I. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg212 · Cited by 503
Comprehensive medicinal chemistry II
Taylor, J. B. (2007) · Cited by 468
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
Pan, X. S., Ambler, J., Mehtar, S., & Fisher, L. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2321 · Cited by 437
Levine, C., Hiasa, H., & Marians, K. J. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00126-2 · Cited by 391
Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky, A. B., Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11801 · Cited by 378
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Mcmurry, L. (1998) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(98)00347-4 · Cited by 354
Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
Self-citationVan Bambeke, F., Michot, J.-M., Van Eldere, J., & Tulkens, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01131.x · Cited by 342
Mechanisms of quinolone action and resistance: where do we stand?
Correia, S., Poeta, P., Hébraud, M., Capelo, J. L., & Igrejas, G. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000475 · Cited by 332
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Mode of Action of Fluoroquinolones
Hooper, D. C. (1999) · Drugs · doi:10.2165/00003495-199958002-00002 · Cited by 290
Mechanisms of quinolone action and microbial response
Hawkey, P. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg207 · Cited by 288
Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”: Miniperspective
Bisacchi, G. S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501881c · Cited by 252
Pan, X. S., & Fisher, L. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.471 · Cited by 237
Comparative Tolerability of the Newer Fluoroquinolone Antibacterials
Ball, P., Mandell, L., Niki, Y., & Tillotson, G. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00005 · Cited by 228
Control of Fluoroquinolone Resistance through Successful Regulation, Australia
Cheng, A. C., Turnidge, J., Collignon, P., Looke, D., Barton, M., & Gottlieb, T. (2012) · Emerging Infectious Diseases · doi:10.3201/eid1809.111515 · Cited by 219
The safety profile of the fluoroquinolones
Bertino, J., & Fish, D. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80053-3 · Cited by 218
DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae
Pan, X.-S., & Fisher, L. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2810 · Cited by 215
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli
Hooper, D. C., Wolfson, J. S., Souza, K. S., Tung, C., McHugh, G. L., & Swartz, M. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.4.639 · Cited by 211
Zhao, X., & Drlica, K. (2002) · The Journal of Infectious Diseases · doi:10.1086/338571 · Cited by 210
Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects.
Sharma, P. C., Jain, A., & Jain, S. K. (2010) · PubMed · Cited by 196
Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde
Anderson, V., & Osheroff, N. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013398013 · Cited by 190
Forterre, P., & Gadelle, D. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp032 · Cited by 186
Peterson, L. R. (2001) · Clinical Infectious Diseases · doi:10.1086/321846 · Cited by 183
Clinical toxicological aspects of fluoroquinolones
Stahlmann, R. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00509-4 · Cited by 173
Update on the treatment of Pseudomonas aeruginosa pneumonia
El Solh, A. A., & Alhajhusain, A. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp201 · Cited by 172
Fluoroquinolone-Gyrase-DNA Complexes
Mustaev, A., Malik, M., Zhao, X., Kurepina, N., Luan, G., Oppegard, L. M., Hiasa, H., Marks, K. R., Kerns, R. J., Berger, J. M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529164 · Cited by 172
Aldred, K. J., McPherson, S. A., Turnbough, C. L., Kerns, R. J., & Osheroff, N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt124 · Cited by 171
Fluoroquinolone resistance in Salmonella: insights by whole-genome sequencing
Cuypers, W. L., Jacobs, J., Wong, V., Klemm, E. J., Deborggraeve, S., & Van Puyvelde, S. (2018) · Microbial Genomics · doi:10.1099/mgen.0.000195 · Cited by 171
Peloquin, C. A. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100083020 · Cited by 167
Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates
Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., & Zechiedrich, L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00665-08 · Cited by 161
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus
Ito, H., Yoshida, H., Bogaki-Shonai, M., Niga, T., Hattori, H., & Nakamura, S. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2014 · Cited by 158
Temafloxacin Syndrome: Review of 95 Cases
Blum, M. D., Graham, D. J., & McCloskey, C. A. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.6.946 · Cited by 154
History of Quinolones and Their Side Effects
Rubinstein, E. (2001) · Chemotherapy · doi:10.1159/000057838 · Cited by 153
Vetting, M. W., Park, C. H., Hegde, S. S., Jacoby, G. A., Hooper, D. C., & Blanchard, J. S. (2008) · Biochemistry · doi:10.1021/bi800664x · Cited by 146
Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death
Wang, X., Zhao, X., Malik, M., & Drlica, K. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp486 · Cited by 141
Caekenberghe, D. L. V., & Pattyn, S. R. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.4.518 · Cited by 125
Price, L. B., Vogler, A. J., Pearson, T., Busch, J. D., Schupp, J. M., & Keim, P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2362-2365.2003 · Cited by 118
Sánchez, M. B., Hernández, A., Rodríguez-Martínez, J. M., Martínez-Martínez, L., & Martínez, J. L. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-148 · Cited by 114
Fournier, B., Zhao, X., Lu, T., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2160-2165.2000 · Cited by 112
Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy
Lee, B. L., Padula, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E., Mills, J., & Sande, M. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250719 · Cited by 112
Piddock, L. J. V., Johnson, M. M., Ricci, V., & Hill, S. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2956 · Cited by 95
Hooper, D. C. (1995) · Drugs · doi:10.2165/00003495-199500492-00004 · Cited by 93
Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents
Menzies, D. J., Dorsainvil, P. A., Cunha, B. A., & Johnson, D. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01158-0 · Cited by 88
SOS response and its regulation on the fluoroquinolone resistance.
Qin, T., Kang, H., Ma, P., Li, P.-P., Huang, L., & Gu, B. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.12.09 · Cited by 84
Structure of QnrB1, a Plasmid-mediated Fluoroquinolone Resistance Factor
Vetting, M. W., Hegde, S. S., Wang, M., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.226936 · Cited by 83
Goldman, J. D., White, D. G., & Levy, S. B. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1266 · Cited by 80
Croisier, D., Etienne, M., Bergoin, E., Charles, P., Lequeu, C., Piroth, L., Portier, H., & Chavanet, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1699-1707.2004 · Cited by 80
Acute Eosinophilic Hepatitis from Trovafloxacin
Chen, H. J. L., Bloch, K. J., & Maclean, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420517 · Cited by 74
Bidell, M. R., Palchak, M., Mohr, J., & Lodise, T. P. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02505-15 · Cited by 72
Mechanisms for Defining Supercoiling Set Point of DNA Gyrase Orthologs
Tretter, E. M., & Berger, J. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.345678 · Cited by 70
Aldred, K. J., Schwanz, H. A., Li, G., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400592n · Cited by 69
Singh, S., & Nautiyal, A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.06.029 · Cited by 65
Fujimoto-Nakamura, M., Ito, H., Oyamada, Y., Nishino, T., & Yamagishi, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3810-3815.2005 · Cited by 63
Hiramatsu, K., Igarashi, M., Morimoto, Y., Baba, T., Umekita, M., & Akamatsu, Y. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.02.007 · Cited by 62
Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions
Sissi, C., Perdonà, E., Domenici, E., Feriani, A., Howells, A. J., Maxwell, A., & Palumbo, M. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4838 · Cited by 59
Mechanisms for Defining Supercoiling Set Point of DNA Gyrase Orthologs
Tretter, E. M., & Berger, J. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.345736 · Cited by 59
Allen, G. P., Kaatz, G. W., & Rybak, M. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2606-2614.2003 · Cited by 54
Appropriate antibiotic treatment of genitourinary infections in hospitalized patients
Liu, H. B., & Mulholland, S. G. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.009 · Cited by 53
MOXIFLOXACIN VERSUS CEPHALEXIN IN THE TREATMENT OF UNCOMPLICATED SKIN INFECTIONS
Parish, L., Routh, H., Miskin, B., Fidelholtz, J., Werschler, P., Heyd, A., Haverstock, D. C., & Church, D. (2000) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2000.tb10911.x · Cited by 51
Sanfilippo, C. M., Hesje, C. K., Haas, W., & Morris, T. W. (2011) · Chemotherapy · doi:10.1159/000330858 · Cited by 46
Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones
German, N. A., Malik, M., Rosen, J. D., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00330-08 · Cited by 44
Nix, D. E., Sands, M. F., Peloquin, C. A., et al. (1987) · PubMed · Cited by 37
Cornett, E. M., Novitch, M. B., Kaye, A. D., Pann, C. A., Bangalore, H. S., Allred, G., Bral, M., Jhita, P. K., & Kaye, A. M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1362938 · Cited by 33
Almalki, Z. S., Yue, X., Xia, Y., Wigle, P. R., & Guo, J. J. (2016) · PharmacoEconomics - Open · doi:10.1007/s41669-016-0007-y · Cited by 32
Oizumi, N., Kawabata, S., Hirao, M., Watanabe, K., Okuno, S., Fujiwara, T., & Kikuchi, M. (2001) · Journal of Infection and Chemotherapy · doi:10.1007/s101560100034 · Cited by 28
Mechanisms of quinolone phototoxicity
Shimoda, K. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00234-3 · Cited by 28
Aedo, S. J., & Tse‐Dinh, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01182-12 · Cited by 26
Inhibition of Human Topoisomerase IIalpha by Fluoroquinolones and Ultraviolet A Irradiation
Perrone, C. E., Takahashi, K. C., & Williams, G. M. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.16 · Cited by 22
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Bhatt, S., & Chatterjee, S. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.120440 · Cited by 428
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Halawa, E. M., Fadel, M., Al-Rabia, M. W., Behairy, A., Nouh, N. A., Abdo, M., Olga, R., Fericean, L., Atwa, A. M., El-Nablaway, M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1305294 · Cited by 280
A Beginner’s Guide to Cell Culture: Practical Advice for Preventing Needless Problems
Weiskirchen, S., Schröder, S. K., Buhl, E. M., & Weiskirchen, R. (2023) · Cells · doi:10.3390/cells12050682 · Cited by 148
Metadata
- Authors
- Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T.
- Venue
- MedChemComm
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 10
- Issue
- 10
- Pages
- 1719-1739
- ISSN
- 2040-2503 (ISSN-L)
- 2040-2511
- OpenAlex
- W4211126900
- Cited by
- 785
- References
- 92
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.